Ascentage Pharma and Innovent Announce the China NMPA Accepted and Granted Priority Review Designation to a New Drug Application for Olverembatinib for the Treatment of Drug-Resistant CML

Ascentage Pharma and Innovent Biologics, Inc. announced that the Center for Drug Evaluation of China National Medical Products Administration (NMPA) has accepted and granted Priority Review designation to a New Drug Application that will support the full approval of olverembatinib in patients with chronic-phase chronic myeloid leukemia (CML) who are resistant and/or intolerant of first- and second-generation tyrosine kinase inhibitors.